Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.

Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.

Abstract: Provided are energy device control systems for distributed grid subsystem that control a first power demand of a plurality of appliances. The control system comprises a graphical user interface configured to accept a user input indicative of a first demand and dynamic allocation flexibility associated with the a respective energy device; a communication interface configured to aggregate dynamic allocation values from a plurality of system nodes including at least the user input indicative of a first demand and the dynamic allocation flexibility; and at least one processor programmed to: generate a learning model for evaluating dynamic future allocation with future energy execution prediction, wherein the dynamic future allocation includes at least energy operational information based on a categorization of energy usage at a plurality of respective energy devices; and trigger energy generation on the energy grid at respective generator nodes according to the learning model and dynamic projections.

Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.

Abstract: A sensor node includes a sensor node printed circuit board, a sensor module, and a communication module. The sensor node printed circuit board manages power of the sensor node circuitry, the sensor module and the communication module such that power is provided from a primary power supply supplemented by a secondary power supply. The sensor module includes a plurality of air quality sensors to measure the concentration of air pollutants. The sensor module may be replaceable. The communication module may communicate air quality measurements to and receive configurations from a data management platform, which may perform processes to improve the accuracy of the air quality measurements.

Abstract: The present invention is directed to sarcophagine based compounds of formula (I). The compounds can complex a radioisotope, such as 64-copper and hence are useful in radioimaging and radiotherapy of cancers, e.g. colorectal cancer. The compounds work via a pre-targeting imaging approach in which the tetrazine reacts via click chemistry with a functional group such as a transcyclooctene which is pre-bound to a ligand such as a tumour specific antibody.

Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.

Abstract: Radiopharmaceutical compounds of general Formula (I) are based on a sarcophagine cage having a PEG linker-group X through to a group Y capable of binding to a biological receptor and an albumin-binding group Z for the treatment, diagnosis or imaging of diseases including cancer, and the production of such compounds and their complexes.

Abstract: An AC power supply for connection to at least one electrode of an electrodynamic screen includes a DC-to-DC converter electrically coupled to a source of DC voltage including an output. The system includes a DC-to-AC converter electrically coupled to the output of the DC-to-DC converter, including a two-terminal passive element electrically coupled in series with a first transistor including a control terminal electrically coupled to a periodic voltage signal configured to switch the first transistor between an on/off state. The system includes an AC output including an AC voltage configured to change periodically. The system includes a regulator circuit configured to sample the AC output voltage and detect when the AC output voltage reaches a predetermined voltage. The regulator circuit is configured to electrically couple the power supply to the source of DC voltage when the output voltage is less than the predetermined voltage.

Abstract: A device includes a wearable portion and a support portion. The wearable portion includes an elongate member and a coupler connected to the elongate member. The elongate member is formed in a loop such that the elongate member is positionable around a neck of a user with the coupler positioned on a torso of the user. The support portion includes an attachment member, an arm, and a retainer. The arm extends from a first end to a second end. The first end is coupled to the attachment member. The retainer is coupled to the second end of the arm and is configured to retain a personal electronic device. The attachment member is releasably attachable to the coupler such that with the attachment member attached to the coupler the device supports the personal electronic device.

Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.

Abstract: Provided are energy device control systems for distributed grid subsystem that control a first power demand of a plurality of appliances. The control system comprises a graphical user interface configured to accept a user input indicative of a first demand and dynamic allocation flexibility associated with the a respective energy device; a communication interface configured to aggregate dynamic allocation values from a plurality of system nodes including at least the user input indicative of a first demand and the dynamic allocation flexibility; and at least one processor programmed to: generate a learning model for evaluating dynamic future allocation with future energy execution prediction, wherein the dynamic future allocation includes at least energy operational information based on a categorization of energy usage at a plurality of respective energy devices; and trigger energy generation on the energy grid at respective generator nodes according to the learning model and dynamic projections.

Abstract: Composition and methods for treating brain “plaques” and/or “tangles” in a subject wherein the method comprises administration of a therapeutically effective amount of a composition comprising a black currant extract, Uncaria tomentosa extract, and an oolong tea extract.

Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.

Abstract: The present invention relates to formulations of radiolabeled compounds that are of use in radiotherapy and diagnostic imaging related to prostate specific membrane antigen (PSMA).

Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.

Abstract: Provided are energy device control systems for distributed grid subsystem that control a first power demand of a plurality of appliances. The control system comprises a graphical user interface configured to accept a user input indicative of a first demand and dynamic allocation flexibility associated with the a respective energy device; a communication interface configured to aggregate dynamic allocation values from a plurality of system nodes including at least the user input indicative of a first demand and the dynamic allocation flexibility; and at least one processor programmed to: generate a learning model for evaluating dynamic future allocation with future energy execution prediction, wherein the dynamic future allocation includes at least energy operational information based on a categorization of energy usage at a plurality of respective energy devices; and trigger energy generation on the energy grid at respective generator nodes according to the learning model and dynamic projections.

Abstract: A sensor node includes a sensor node printed circuit board, a sensor module, and a communication module. The sensor node printed circuit board manages power of the sensor node circuitry, the sensor module and the communication module such that power is provided from a primary power supply supplemented by a secondary power supply. The sensor module includes a plurality of air quality sensors to measure the concentration of air pollutants. The sensor module may be replaceable. The communication module may communicate air quality measurements to and receive configurations from a data management platform, which may perform processes to improve the accuracy of the air quality measurements.

Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.